Summary of Lantheus Conference Call Company Overview - **Company**: Lantheus - **Industry**: Healthcare, specifically in radiopharmaceuticals and diagnostics Key Points and Arguments 1. **Competitive Landscape**: Lantheus faced significant challenges in 2025, particularly with its flagship product PYLARIFY, due to increased competition and the loss of pass-through status affecting reimbursement rates for Medicare patients [7][8][9] 2. **FDA Approvals**: The company received two FDA approvals in recent weeks: a conditional approval for PNT2003 and full approval for PYLARIFY TruVu, which is expected to enhance market competitiveness and customer engagement [8][9] 3. **Future Growth Strategy**: Lantheus is positioning itself for growth in 2026 and beyond, focusing on consolidating its portfolio in nuclear medicine and re-engaging price-sensitive customers who switched to competitors [9][11] 4. **Market Dynamics**: The PSMA PET franchise is expected to stabilize, with projected market volume growth of 10%-11% in 2026, down from 20% in 2025 [31][32] 5. **Manufacturing Advantages**: PYLARIFY TruVu offers significant manufacturing improvements, allowing for up to 50% more doses per batch, addressing customer demand for increased availability [36][37] 6. **Alzheimer's Diagnostics**: The total addressable market (TAM) for Alzheimer's diagnostics is projected to reach $1.5 billion by the end of the decade, driven by the approval of new therapeutic drugs and changes in reimbursement guidelines [49][50] 7. **Capital Allocation**: Lantheus plans to pause on large business development (BD) initiatives to focus on integrating recent acquisitions and optimizing existing product lines [54][55] 8. **Reimbursement Strategy**: The company anticipates a smooth transition to PYLARIFY TruVu, with expectations for transitional pass-through coverage to be effective by October, which will aid in market adoption [65][66] Additional Important Insights 1. **Sales and Marketing Focus**: The company plans to invest 12%-12.5% of revenue in sales and marketing to support the launch of PYLARIFY TruVu and other products [60] 2. **Contracting Dynamics**: Transitioning to PYLARIFY TruVu will involve amending existing contracts rather than creating new ones, which is expected to streamline the process [19][20] 3. **Market Education**: Lantheus aims to raise awareness about the role of radiopharmaceuticals in life sciences, emphasizing their unique market dynamics compared to traditional pharmaceuticals [68][69] This summary encapsulates the critical aspects of Lantheus' current position, strategic direction, and market outlook as discussed in the conference call.

Summary of Lantheus Conference Call Company Overview - **Company**: Lantheus - **Key Executives**: Mary Anne Heino (CEO), Bob Marshall (CFO) - **Event**: TD Cowen's 46th Annual Healthcare Conference Core Industry Insights - **Focus on Diagnostics**: Lantheus has strategically chosen to focus on its diagnostic assets over therapeutic assets, citing a broad portfolio that was too extensive for the company's current scale and capitalization [3][4] - **Recent Acquisitions**: The company completed significant M&A activities in 2025, acquiring LMI and Evergreen, which contributed to the expanded portfolio [4] Key Product Developments - **PYLARIFY Launch**: The new formulation of PYLARIFY is set to launch, with key milestones including obtaining coding, coverage, and reimbursement. The company aims for pass-through status by October 1, 2026, and HCPCS code submission by April 1, 2026 [6][9][12] - **Increased Production Capacity**: The new formulation is expected to yield up to 50% more doses per batch compared to the current formulation, enhancing market availability [14][15] - **PNT2003 Asset**: Lantheus received conditional FDA approval for PNT2003, which is positioned as a radio equivalent to Lutathera. The company is preparing for commercialization, pending the expiration of the Hatch-Waxman litigation period [5][38][39] Financial Guidance - **Revenue Projections**: For 2026, Lantheus provided revenue guidance of $1.4 billion to $1.45 billion, adjusted for a $111 million divestiture of the SPECT business. The guidance reflects a year-over-year comparison [18][19] - **EPS Guidance**: The company anticipates an EPS of approximately $575 million, with investments in sales and marketing expected to be around 12%-12.5% of revenue [55] Market Dynamics - **Competitive Landscape**: Lantheus is aware of competitors like Telix and their new formulations. The company is monitoring pricing strategies and market dynamics closely [21] - **Alzheimer's Imaging Market**: Lantheus is developing multiple products for Alzheimer's, including NeuroSeq and MK-6240, with a focus on both beta-amyloid and tau imaging. The market is seen as large and underserved, with potential for significant growth [25][27][28] Strategic Decisions - **Shift from Therapeutics**: The decision to focus on diagnostics over therapeutics is based on lower development costs and higher success probabilities in radiopharmaceuticals. The company aims to leverage its expertise in this area [40][42][43] - **OCTEVY Rollout**: The acquisition of OCTEVY is seen as complementary to Lantheus's existing portfolio, targeting near-term revenue opportunities [49] Underappreciated Aspects - **Market Education**: The CEO emphasized the importance of educating investors about radiopharmaceuticals and believes the stock is undervalued due to a lack of understanding in the market [60][61] This summary encapsulates the key points discussed during the conference call, highlighting Lantheus's strategic focus, product developments, financial guidance, and market dynamics.

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $406.8 million, an increase of 4% year-over-year, while full-year revenue was $1.546 billion, up 0.5% [20] - Adjusted EPS for Q4 was $1.67, an increase of 4.7%, while full-year adjusted EPS was $6.08, a decrease of 10% from the prior year [26][30] - Operating cash flow for Q4 totaled $90.2 million, down from $157.7 million in Q4 2024 [27] Business Line Data and Key Metrics Changes - Radiopharmaceutical oncology, primarily from PYLARIFY, generated Q4 revenue of $240.2 million, down 9.7% year-over-year, and full-year revenue of $989.1 million, down 6.5% [20] - Precision Diagnostics delivered Q4 revenue of $143.2 million, a 22% increase, driven by DEFINITY and Neuraceq, which contributed $31 million in Q4 [21][14] - Strategic partnerships and other revenue increased by 203.3% to $23.3 million, largely due to MK-6240 [22] Market Data and Key Metrics Changes - PYLARIFY's volume grew approximately 4% year-over-year, with pricing discipline contributing to performance despite competitive pressures [12] - Neuraceq is expected to grow triple digits in 2026, driven by increased demand for Alzheimer's imaging [14] - DEFINITY maintained over 80% market share, delivering over $85 million in Q4 [14] Company Strategy and Development Direction - The company is focusing on radiodiagnostics, with plans to maintain leadership in PSMA PET imaging and prepare for the launch of a new PSMA PET formulation in Q4 2026 [8][36] - The strategic intent includes optimizing the cost structure and prioritizing investments in innovative PET radiodiagnostics [10] - The company plans to pursue value-maximizing alternatives for its radiotherapeutic assets while focusing on diagnostic opportunities [11][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive meaningful performance gains and deliver sustainable revenue growth in the mid and long term [11][36] - The company anticipates several product approvals in 2026, with a focus on commercial execution and regulatory milestones [30] - Management highlighted the importance of maintaining operational excellence and customer relationships to support growth [13] Other Important Information - The company completed the divestiture of its legacy SPECT business on January 1, 2026, to focus on PET radiodiagnostics [8] - The effective tax rate for Q4 was 19%, with a full-year rate of 25.3% [25] - Cash and cash equivalents stood at $359.1 million, with $200 million remaining for share buybacks [28] Q&A Session Summary Question: What is the timing for the new PSMA PET imaging agent's coding and reimbursement? - Management anticipates securing HCPCS code and transitional pass-through status by October 1, 2026, with a regional rollout planned for Q4 2026 [41][42] Question: How does the POSLUMA versus PYLARIFY study impact market dynamics? - Management expressed concerns about the study design and stated that its results do not factor into the current forecast for PYLARIFY [46][48] Question: Can you elaborate on pricing and unit growth for PYLARIFY in Q4? - Management indicated that Q4 performance exceeded expectations, with both volume growth and favorable pricing contributing to results [52] Question: What are the plans for radiotherapeutic assets? - Management is reviewing therapeutic assets for value optimization and may consider tuck-in acquisitions for diagnostic opportunities [61][62] Question: What is the growth outlook for Neuraceq? - Management expects Neuraceq to achieve triple-digit growth in 2026, supported by expanded manufacturing and deeper penetration in existing accounts [14][66]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $406.8 million, an increase of 4% year-over-year, while full-year revenue was $1,541.6 million, up 0.5% from the previous year [20][21] - Adjusted GAAP fully diluted earnings per share for Q4 were $1.67, an increase of 4.7%, while for the full year, it was $6.08, a decrease of 10% [26][30] - Gross profit margin for Q4 was 65.1%, down 289 basis points from Q4 2024, primarily due to decreases in PYLARIFY net price [22] Business Line Data and Key Metrics Changes - Radiopharmaceutical oncology, solely comprised of PYLARIFY, generated Q4 revenue of $240.2 million, down 9.7% year-over-year, and full-year revenue of $989.1 million, down 6.5% [20][21] - Precision Diagnostics delivered Q4 revenue of $143.2 million, a 22% increase, driven by DEFINITY's sales of $85.3 million [21] - Neuraceq contributed $31 million in Q4 and $51.4 million since its acquisition in late July [21][14] Market Data and Key Metrics Changes - The market for PYLARIFY is expected to see a decline of 8%-10% year-over-year due to increased competition and pricing dynamics [30][45] - Neuraceq is projected to grow triple digits in 2026, driven by increased demand for Alzheimer's imaging [14][31] - DEFINITY is expected to grow in the low to mid-single digits in 2026 [31] Company Strategy and Development Direction - The company is focusing on radiodiagnostics, with plans to maintain leadership in PSMA PET imaging and prepare for the launch of a new PSMA PET formulation in Q4 2026 [8][10] - The strategic intent includes divesting the legacy SPECT business to prioritize innovative PET radiodiagnostics [8][11] - The company aims to optimize its cost structure and selectively pursue value-maximizing alternatives for radiotherapeutic assets [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive performance gains and deliver sustainable revenue growth in the mid and long term [11][36] - The focus for 2026 will be on commercial execution and regulatory milestones, with expectations for several product approvals [11][30] - Management acknowledged the importance of maintaining operational excellence and customer relationships to support growth [13][14] Other Important Information - The company repurchased $100 million of its own shares during Q4 2025, leaving $200 million of authorization for buybacks outstanding [28] - The effective tax rate for Q4 was 19%, with an expected increase to 26% in 2026 [25][32] Q&A Session Summary Question: What is the timing for the new PSMA PET imaging agent's coding and reimbursement? - Management anticipates securing HCPCS coding and transitional pass-through status by October 1st, with a commercial rollout planned for Q4 2026 [41][42] Question: How does the study comparing PYLARIFY and POSLUMA impact market dynamics? - Management expressed concerns about the study design and stated that the results do not factor into their forecast for PYLARIFY [46][48] Question: Can you elaborate on pricing and unit growth in Q4 2025? - Management reported a 4% volume growth for PYLARIFY in Q4, with expectations for low single-digit growth in 2026 [52][54] Question: What are the plans for radiotherapeutic assets? - Management is reviewing the therapeutic assets for value optimization and may consider tuck-in acquisitions for diagnostic opportunities [60][62] Question: What is the growth outlook for Neuraceq? - Management expects triple-digit growth for Neuraceq in 2026, driven by expanding manufacturing and market penetration [14][66]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $406.8 million, an increase of 4% year-over-year, while full-year revenue was $1,541.6 million, up 0.5% [21] - Gross profit margin for Q4 was 65.1%, down 289 basis points from Q4 2024, primarily due to decreases in PYLARIFY net price [23] - Operating profit for Q4 was $138.9 million, a decrease of 8.5%, with reported profit for Q4 at $54.1 million [26] Business Line Data and Key Metrics Changes - Radiopharmaceutical oncology, solely comprised of PYLARIFY, generated Q4 revenue of $240.2 million, down 9.7% year-over-year, and full-year revenue of $989.1 million, down 6.5% [21] - Precision Diagnostics delivered Q4 revenue of $143.2 million, a 22% increase, driven by DEFINITY and Neuraceq, which contributed $31 million in Q4 [22][14] - Strategic partnerships and other revenue was $23.3 million, up 203.3%, due to strong performance from MK-6240 [22] Market Data and Key Metrics Changes - PYLARIFY volume increased approximately 4% year-over-year, with pricing concessions resetting 340B pricing in Q4 2025 [12] - Neuraceq is positioned as the second-most utilized and fastest-growing beta-amyloid PET imaging agent, addressing a large and expanding market [15] - DEFINITY maintained over 80% market share, delivering over $85 million in Q4 [15] Company Strategy and Development Direction - The company is focusing on radiodiagnostics, having divested its legacy SPECT business to prioritize innovative PET radiodiagnostics [8] - The strategy includes maintaining leadership in PSMA PET imaging with PYLARIFY and preparing for the launch of a new PSMA PET formulation in Q4 2026 [8][36] - The company plans to maximize the value of its current product portfolio while selectively developing pipeline assets and optimizing the therapeutic pipeline [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive meaningful performance gains and deliver sustainable revenue growth in the mid and long term [11] - The focus for 2026 will be on commercial execution and regulatory milestones, with expectations for multiple FDA approvals [9][11] - Management highlighted the importance of maintaining operational excellence and customer relationships to support growth [12] Other Important Information - The company repurchased $100 million of its own shares during Q4, leaving $200 million of authorization for buybacks outstanding [28] - The effective tax rate was 19% for Q4 and 25.3% for the full year [26] - The company anticipates a revenue forecast of $1.4 billion to $1.45 billion for 2026, with PYLARIFY expected to decline 8%-10% year-over-year [31] Q&A Session Summary Question: What will be the timing for securing coding and reimbursement for the new PSMA PET imaging agent? - Management anticipates securing HCPCS code and transitional pass-through status by October 1st, with a commercial rollout planned for Q4 2026 [42][43] Question: How does the study comparing PYLARIFY and POSLUMA impact the forecast? - Management expressed concerns about the study design and stated that the results do not impact their forecast [46][49] Question: Can you elaborate on pricing and unit growth in Q4 2025? - Management noted a strong quarter for PYLARIFY, with volume growth of 4% and a favorable pricing environment [51][52] Question: What are the plans for radiotherapeutic assets? - The company is reviewing its therapeutic assets and considering value-maximizing alternatives while focusing on diagnostic assets [60][62] Question: What is the growth potential for Neuraceq? - Management expects triple-digit growth for Neuraceq, driven by expanding manufacturing and deeper penetration in existing accounts [66][68]

Financial Performance - Lantheus' Q2 2025 revenues were $378 million, a decrease of 4.1% compared to Q2 2024[15, 52] - Adjusted EPS for Q2 2025 was $1.57, a decrease of 12.8% year-over-year[15, 52] - Radiopharmaceutical Oncology sales were $250.6 million, down 8.3% year-over-year, but with a 4% sequential volume increase[52] - Precision Diagnostics sales were $115.8 million, up 3.3% year-over-year, driven by DEFINITY sales growth of 7.5%[52] - Strategic Partnerships sales were $11.6 million, up 32.8% year-over-year[52] Financial Position - Cash provided by operations increased to $87.1 million in Q2 2025 from $84.7 million in Q2 2024[55] - Free cash flow for Q2 2025 was $79.1 million[58] - Lantheus has $695.6 million in cash on hand and $750 million available in revolving credit[58] Guidance - Updated FY 2025 revenue guidance is $1.475 billion - $1.51 billion[61] - Updated FY 2025 adjusted fully diluted EPS guidance is $5.50 - $5.70[61] Strategic Initiatives - Lantheus anticipates four key product launches in the next 18 months: MK-6240, OCTEVY, PNT2003, and a new PSMA PET formulation[20] - The company has a board authorization for a new $400 million stock repurchase program[59]

Financial Performance & Guidance - Lantheus' Q1 2025 revenues reached $372.8 million, reflecting a 0.8% increase[9] - The company's updated full-year 2025 revenue guidance is $1.55 billion to $1.585 billion[17] - The updated adjusted fully diluted EPS guidance for 2025 is $6.60 to $6.70[17] - As of March 31, 2025, Lantheus had $938.5 million in cash on hand and $750 million available in revolving credit[17, 18] Acquisitions & Divestments - Lantheus closed the acquisition of Evergreen Theragnostics in April 2025[9] - The company anticipates closing the acquisition of Life Molecular Imaging in Q2 2025[9] - Lantheus plans to finalize the divestment of its SPECT business by the end of 2025[9] Key Products & Market - PYLARIFY net sales were $257.7 million in Q1 2025, and it is the 1 utilized PSMA PET imaging agent[26, 24] - 99% of enrolled patients in the CONDOR study experienced a change in intended patient management based on PYLARIFY results[29] - The PSMA PET market may exceed $3.5 billion by the end of the decade[38] - DEFINITY net sales were $79.2 million in Q1 2025, with a 3.5% year-over-year growth, remaining the 1 utilized ultrasound enhancing agent[61] - The U S Ultrasound Enhancing Agent TAM is $600M+[68] Pipeline & Development - Lantheus is advancing a diversified radiotherapeutic and radiodiagnostic pipeline, including MK-6240 for Tau imaging and NAV-4694 for β amyloid imaging in Alzheimer's disease[71, 74] - PNT2003, a somatostatin receptor (SSTR)-targeted radiotherapeutic, has a potential launch in 2026[75] - LNTH-2401/2402 (GRPR-targeted) are in development for metastatic prostate cancer, with an IND filing for LNTH-2401 expected in Q4 2025 and Phase 1 initiation for LNTH-2402 planned for 2026[141]

Commercial Portfolio Performance - PYLARIFY achieved blockbuster status in 2024 with over $1 billion in sales[154], and Q1 2025 net sales reached $257.7 million[13] - DEFINITY remains the 1 utilized ultrasound enhancing agent, with Q1 2025 net sales of $79.2 million, a 3.5% year-over-year growth[24] Market Opportunities - The U S PSMA PET imaging market has a potential of over $3.5 billion by 2030, driven by expansion of radiotherapeutics and increasing clinical utility in BCR population[19, 20] - The U S ultrasound enhancing agent total addressable market is over $600 million[35] Pipeline Development - Lantheus is advancing an innovative pipeline of radiopharmaceuticals, including diagnostic and therapeutic candidates for prostate cancer, neuroendocrine tumors, and Alzheimer's disease[38, 40] - LNTH-2402, a GRPR-targeted radiotherapeutic, is expected to have an IND filing in Q4 2025, with Phase 1 initiation planned for 2026[109] Financial Highlights - As of March 31, 2025, Lantheus had $938.5 million in cash on hand and $98.8 million in free cash flow in Q1 2025[10] - The updated interim corporate financial guidance for the full year 2025 projects revenue between $1.550 billion and $1.585 billion, and adjusted fully diluted EPS between $6.60 and $6.70[142] Strategic Transactions - The acquisition of Evergreen Theragnostics closed in April 2025, strengthening radiodiagnostic and therapeutic capabilities[10, 165] - The acquisition of Life Molecular Imaging is expected to close by 2Q 2025, expanding the commercial portfolio and pipeline in Alzheimer's disease[10, 144]

Financial Data and Key Metrics Changes - Consolidated net revenue for Q1 2025 was $372.8 million, an increase of 0.8% year-over-year [24] - GAAP net income for Q1 was $72.9 million, with adjusted net income at $109.5 million, a decrease of 7.5% [29] - Gross profit margin for Q1 was 67%, a decrease of 180 basis points compared to the previous year [25] - Operating profit for the quarter was $144.3 million, a decrease of 7.1% [27] Business Line Data and Key Metrics Changes - Radiopharmaceutical oncology, primarily from Polarify, contributed $257.7 million in sales, flat year-over-year [24] - Precision Diagnostic revenue was $104.4 million, also flat year-over-year, with DEFINITY sales at $79.2 million, up 3.5% [25] - Strategic partnerships and other revenue increased by 65.1% to $10.7 million, driven by investigational asset MK6240 [25] Market Data and Key Metrics Changes - The U.S. Alzheimer's disease radio diagnostics total addressable market is projected to grow to over $1.5 billion by the end of the decade and $2.5 billion by the mid-2030s [11] - The PSMA PET addressable market is anticipated to exceed $3.5 billion by 2026, driven by rising disease incidence and broader adoption [15] Company Strategy and Development Direction - The company plans to divest its SPECT business to Shine Technologies to focus on PET radio diagnostics and radiotherapeutics [5][12] - Recent acquisitions of Evergreen Theranostics and Life Molecular Imaging are aimed at enhancing radiopharmaceutical leadership and long-term growth [5][6] - The company is committed to advancing its position in nuclear medicine through both organic growth and strategic acquisitions [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining market leadership despite competitive pressures and pricing dynamics [41] - The divestiture of the SPECT business is expected to unlock future revenue growth and gross margin expansion [46] - The company anticipates low single-digit dilution from the combined addition of Evergreen and LMI, with an updated revenue guidance of $1.55 to $1.585 billion for 2025 [32][34] Other Important Information - The company is actively monitoring tariff activities and their potential impact on operations, though current effects are minimal [30] - R&D expenses are expected to be approximately 7.5% of revenue, reflecting increased investments in growth initiatives [33] Q&A Session Summary Question: Can you elaborate on Polarify trends and competitive dynamics? - Management noted successful revenue stabilization through strategic partnerships, despite experiencing short-term competitive disruption among smaller non-contracted sites [40][41] Question: What is the rationale for exiting the SPECT business now? - The SPECT business is viewed as non-core to future growth, allowing the company to streamline operations and focus on higher growth areas [45][46] Question: How does the divestiture of the SPECT business free up resources? - The divestiture allows for a sharper organizational focus on PET radio diagnostics and radiotherapeutics, enhancing growth potential [55] Question: What is the expected impact of MUC-based pricing on revenue? - MUC-based pricing currently affects about 20% of patients, with management expecting stabilization as sites adapt to new reimbursement structures [93][95] Question: How does the company view the long-term opportunity for GRPR targeting in prostate cancer? - There is potential for GRPR imaging and therapy to play a significant role in various stages of prostate cancer treatment, with ongoing development efforts [86][88]

Core Insights - Lantheus Holdings, Inc. has completed the acquisition of Evergreen Theragnostics, enhancing its position in the radiopharmaceutical market [1][2][3] - The acquisition includes OCTEVY™, a PET diagnostic imaging agent for neuroendocrine tumors, and a portfolio of theranostic pairs, which complements Lantheus' existing therapeutic candidate PNT2003 [2][3] - This strategic move aims to strengthen Lantheus' capabilities across the entire radiopharmaceutical value chain, from development to manufacturing and commercialization [3] Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, focused on improving patient outcomes through innovative solutions [4] - The company has over 65 years of experience in providing radiopharmaceutical solutions and operates in multiple locations including Massachusetts, New Jersey, Canada, and Sweden [4] - Evergreen Theragnostics specializes in radiopharmaceuticals for cancer treatment and offers CDMO services, with a strong foundation in theragnostic radiopharmaceutical manufacturing [5]